Jian Wu

ORCID: 0000-0001-5719-5820
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Liver Disease Diagnosis and Treatment
  • Bone health and treatments
  • Psoriasis: Treatment and Pathogenesis
  • Cancer Cells and Metastasis
  • Cancer Immunotherapy and Biomarkers
  • Parkinson's Disease Mechanisms and Treatments
  • Breast Lesions and Carcinomas
  • Colorectal Cancer Treatments and Studies
  • RNA modifications and cancer
  • Prostate Cancer Treatment and Research
  • CAR-T cell therapy research
  • Gastric Cancer Management and Outcomes
  • Breast Cancer Treatment Studies
  • Cancer Research and Treatments
  • Vitamin D Research Studies
  • Cancer, Lipids, and Metabolism
  • Heart Rate Variability and Autonomic Control
  • Nutrition, Genetics, and Disease
  • Pancreatic and Hepatic Oncology Research
  • Bone health and osteoporosis research
  • Mitochondrial Function and Pathology
  • Cardiovascular, Neuropeptides, and Oxidative Stress Research
  • Vagus Nerve Stimulation Research
  • Educational Reforms and Innovations
  • Chemotherapy-related skin toxicity

Guizhou University
2022-2025

Jinan University
2019-2024

Zhengzhou University
2022-2024

Suzhou Municipal Hospital
2022-2023

Nanjing Medical University
2016-2022

Changzhou No.2 People's Hospital
2022

Zhejiang University
2014-2022

China Medical University
2022

First Hospital of China Medical University
2022

Shanghai Jiao Tong University
2015-2022

// Xi Zhang 1, * , Xuan-Zhang Huang Wen-Jun Chen 1 Jian Wu You 2 Cong-Cong and Zhen-Ning Wang 3 Department of Chemotherapy Radiotherapy, The Second Affiliated Hospital Yuying Children's Wenzhou Medical University, Lucheng, 325027, P.R. China Pediatric Dentistry, Dental Hospital, Surgical Oncology General Surgery, First Heping, Shenyang 110001, These authors have contributed equally to this work Correspondence to: Wang, email: josieon826@sina.cn Keywords: vitamin D, 25-hydroxyvitamin...

10.18632/oncotarget.18888 article EN Oncotarget 2017-06-29

The present study was performed to examine the association of angiopoietin-like protein 8 (ANGPTL8) rs2278426 single nucleotide polymorphism (SNP) and several environmental factors with serum lipid profiles in Mulao Han populations. A total 879 individuals ethnic group 865 Chinese were included. apolipoprotein (Apo) B level higher, however ApoA1 lower than (P<0.05 P<0.001, respectively). genotypic allelic frequencies, ANGPTL8 SNP different between frequency allele 17.80% 23.04% (P<0.001)....

10.3892/mmr.2015.3825 article EN cc-by-nc Molecular Medicine Reports 2015-05-25

Abstract Nuclear paraspeckle assembly transcript 1 (NEAT1) has been found to be dysregulated and associated with clinical progression in various human cancers. The prognostic value of NEAT1 nasopharyngeal carcinoma (NPC) was still controversial. aim our study provide more sufficient evidence that expression is correlated overall survival patients NPC. detected NPC tissue samples, the relationship between parameters, including prognosis, analyzed. meta‐analysis performed further assess...

10.1002/jcb.28263 article EN Journal of Cellular Biochemistry 2019-01-07

Breast low-grade adenosquamous carcinoma is an uncommon cancer that has been neglected in genetic and pathophysiological research. Consequently, medical practitioners face challenges the effective diagnosis treatment of this condition.

10.1097/md.0000000000039131 article EN cc-by-nc Medicine 2024-07-26

We aimed to evaluate whether elevated serum synuclein-gamma levels were of clinical significance as a serological marker in cancer diagnosis and monitoring.Pre-treatment patients with gastrointestinal esophageal squamous cell carcinomas, benign disease healthy controls analyzed by specific sandwich ELISA for synuclein-gamma.Statistically significant differences between colo rectal cancer, gastric adenocarcinomas, individuals observed (p<0.001). When cut-off value was determined at ≥4 ng/mL...

10.5754/hge12090 article EN Hepatogastroenterology 2012-03-30

Nasopharyngeal carcinoma (NPC) is a malignancy with 2 per 100 000 incidence rate in the world. Overall survival (OS) of patients stage I-II disease around 80%, whereas OS III-IVB drops to 60%, implying importance diagnosis reduce NPC mortality. However, more than 70% were diagnosed at advanced stages (stage III and IV) clinics, it definitely contributes little substantial improvement 5-year rates although sensitive radio-and chemotherapy. Hence, development novel biomarkers targetable genes...

10.1177/01455613221134408 article EN cc-by-nc Ear Nose & Throat Journal 2022-12-28
Coming Soon ...